Introducing revolutionary host response technology to the medical community to solve some of the biggest public health challenges of our time.
Biomeme merged with Predigen to accelerate the work their partnership started years ago developing host gene expression signatures for use as prognostic, diagnostic, and therapeutic monitoring tools. Before the merger, the Predigen team of scientists collectively published over 400 articles in peer reviewed journals, many of which are listed below.
- 09/2009 - Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans
- 08/2011 - Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection
- 01/2013 - A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2
- 09/2013 - A host-based RT-PCR gene expression signature to identify acute respiratory viral infection
- 09/2016 - Host gene expression classifiers diagnose acute respiratory illness etiology
- 01/2016 - A Genomic Signature of Influenza Infection Shows Potential for Presymptomatic Detection, Guiding Early Therapy, and Monitoring Clinical Responses
- 03/2016 - Potential Cost-effectiveness of Early Identification of Hospital-acquired Infection in Critically Ill Patients
- 05/2016 - Transcriptomic Analysis of the Host Response and Innate Resilience to Enterotoxigenic Escherichia coli Infection in Humans
- 02/2018 - A community approach to mortality prediction in sepsis via gene expression analysis
- 06/2018 - Unsupervised Analysis of Transcriptomics in Bacterial Sepsis Across Multiple Datasets Reveals Three Robust Clusters
- 12/2018 - A miRNA Host Response Signature Accurately Discriminates Acute Respiratory Infection Etiologies
- 10/2019 -Validation of a host response test to distinguish bacterial and viral respiratory infection
- 05/2020 - Previously Derived Host Gene Expression Classifiers Identify Bacterial and Viral Etiologies of Acute Febrile Respiratory Illness in a South Asian Population
- 01/2021 - Validation of a host gene expression test for bacterial/viral discrimination in immunocompromised hosts
- 02/2021 - Dysregulated transcriptional responses to SARS-CoV-2 in the periphery
- 03/2021 - A blood-based host gene expression assay for early detection of respiratory viral infection: an index-cluster prospective cohort study
- 07/2021 - The host transcriptional response to Candidemia is dominated by neutrophil activation and heme biosynthesis and supports novel diagnostic approaches
Dr. Christopher Woods is the Co-Director of the Hubert-Yeargan Center for Global Health. He is a professor in the Departments of Medicine and Pathology at Duke University; an adjunct professor in Epidemiology at the University of North Carolina at Chapel Hill School of Public Health; and an adjunct professor in the Emerging Infections Program at the Duke-National University of Singapore Graduate Medical School. Clinically, he serves as Chief of Infectious Diseases and clinical microbiology, and hospital epidemiologist for the Durham VA Health Care System. Dr. Woods is board-certified in internal medicine, infectious diseases, and medical microbiology. He currently serves as the Director of Graduate Studies and the MSc for Global Health in the Duke Global Health Institute.
Dr. Woods has published over 130 peer-reviewed articles and has a particular interest in development of medical microbiology capacity in the developing world and the epidemiology of emerging and re-emerging infectious diseases. His research focuses on the development of novel diagnostic approaches to infectious disease and the potential for interspecies transmission of pathogens. His genomic approach to harnessing the host response for diagnosis of infectious diseases has been called a paradigm shift in the field. Dr. Woods is a partner in the Southeastern Center for Emerging Biological Threats, core PI of the Southeastern Research Center for Excellence on Emerging Infections and Biodefense, and a leader in the NIH-funded Vaccine and Therapeutics Evaluation Unit at Duke.
Dr. Geoffrey Ginsburg is the founding director for the Duke Center for Applied Genomics & Precision Medicine and of Duke MEDx. He also founded Genomic Medicine in the Duke Institute for Genome Sciences & Policy and the Center for Personalized Medicine, established in the Duke University Health System. He is Professor of Medicine, Pathology, and Biomedical Engineering. Dr. Ginsburg has pioneered translational genomics, and has led the development of predictive models for common, complex diseases using high dimensional genomic data. He is an internationally recognized expert in genomics and personalized medicine with over 200 published papers, and funding from NIH, DOD, DARPA, the Gates Foundation, and industry.
He has been a member of the Secretary of Veterans Affairs Advisory Council on Genomic Medicine, a member of the NIGMS External Scientific Panel for the Pharmacogenomics Research Network, the Board of External Experts for the NHLBI, the National Advisory Council for Human Genome Research at NIH, the Advisory Council for the National Center for Advancing Translational Sciences at NIH, and the World Economic Forum’s Global Agenda Council on The Future of the Health Sector. He is co-chair of the National Academies Roundtable on Genomics and Precision Health, founder of the Global Genomic Medicine Collaborative, and a member of the Advisory Committee to the Director of NIH.